NASDAQ:MIRO • US60471P1084
Taking everything into account, MIRO scores 3 out of 10 in our fundamental rating. MIRO was compared to 57 industry peers in the Life Sciences Tools & Services industry. The financial health of MIRO is average, but there are quite some concerns on its profitability. MIRO is valued quite expensive, but it does show an excellent growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.92% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.73 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.39
+0.02 (+0.59%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 96.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.98 | ||
| P/tB | 5.98 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -117.04% | ||
| ROE | -176.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 47.92% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.83% | ||
| Cap/Sales | 23.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | -3.73 |
ChartMill assigns a fundamental rating of 3 / 10 to MIRO.
ChartMill assigns a valuation rating of 0 / 10 to MIROMATRIX MEDICAL INC (MIRO). This can be considered as Overvalued.
MIROMATRIX MEDICAL INC (MIRO) has a profitability rating of 0 / 10.
The financial health rating of MIROMATRIX MEDICAL INC (MIRO) is 4 / 10.
The Earnings per Share (EPS) of MIROMATRIX MEDICAL INC (MIRO) is expected to grow by 32.47% in the next year.